Ribosome display: next-generation display technologies for production of antibodies in vitro.
Antibodies represent an important and growing class of biologic research reagents and biopharmaceutical products. They can be used as therapeutics in a variety of diseases. With the rapid expansion of proteomic studies and biomarker discovery, there is a need for the generation of highly specific binding reagents to study the vast number of proteins encoded by the genome. Display technologies provide powerful tools for obtaining antibodies. Aside from the preservation of natural antibody repertoires, they are capable of exploiting diversity by DNA recombination to create very large libraries for selection of novel molecules. In contrast to in vivo immunization processes, display technologies allow selection of antibodies under in vitro-defined selection condition(s), resulting in enrichment of antibodies with desired properties from large populations. In addition, in vitro selection enables the isolation of antibodies against difficult antigens including self-antigens, and this can be applied to the generation of human antibodies against human targets. Display technologies can also be combined with DNA mutagenesis for antibody evolution in vitro. Some methods are amenable to automation, permitting high-throughput generation of antibodies. Ribosome display is considered as representative of the next generation of display technologies since it overcomes the limitations of cell-based display methods by using a cell-free system, offering advantages of screening larger libraries and continuously expanding new diversity during selection. Production of display-derived antibodies can be achieved by choosing one of a variety of prokaryotic and eukaryotic cell-based expression systems. In the near future, cell-free protein synthesis may be developed as an alternative for large-scale generation of antibodies.
Protein Technologies Laboratory, Babraham Research Campus, Cambridge, CB2 4AT, UK. mingyue.he@bbsrc.ac.uk
Mingyue
M
He
Farid
F
Khan
D000906:Antibodies / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D017123:Bacteriophage T7 / Q000235:genetics; D001666:Binding Sites, Antibody; D014644:Genetic Variation; D016678:Genome; D004364:Pharmaceutical Preparations; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000235:genetics; D012194:RNA-Directed DNA Polymerase; D011995:Recombination, Genetic; D012270:Ribosomes / Q000276:immunology*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D004364:Pharmaceutical Preparations; D012333:RNA, Messenger; D012194:RNA-Directed DNA Polymerase